Levosalbutamol

Research use only, not for human use.

A short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).

A short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).Asthma Approved.

Levalbuterol (10 μM; 24 hours) induces 11β-HSD1 mRNA expression, however, it does not influence 11β-HSD2expression inairway epithelial cells.Levalbuterol (10 μM; 24 hours) significantly reduces both LPS- and TNF-α-induced NF-κB activity while increasing GRE activation in an 11β-HSD1 dependent manner in a transformed mouse airway epithelial cell line. RT-PCR Cell Line:Murine Club (MTCC) cells Concentration:10 μM Incubation Time:24 hours Result:Increased 11β-HSD1 mRNA expression selectively.

Levalbuterol (subcutaneous injection; 1 mg/kg; 14 days) significantly decreases pulmonary inflammation in OVA mice,demonstrated a decrease in eosinophilia and IgE. Animal Model:C57BL/6 female mice?with a pulmonary allergic modelDosage:1 mg/kg Administration:Subcutaneous injection; 1 mg/kg; 14 days Result:Decreased pulmonary inflammation after OVA sensitization.

Levalbuterol

GPCR/G Protein

Adrenergic Receptor

Adrenergic Receptor

Inflammation/Immunology

Asthma

34391-04-3

239.311

C13H21NO3

>98% (HPLC)

——

CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O

(R)-4-(2-(tert-butylamino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol

(-20℃)

With Ice Pack

≥ 2 years